Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  New England Journal of Medicine

• Publication date

  2000-03-16

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJM200003163421103PMID 10717011
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.

  1999cited by this paper
• Etanercept Therapy in Rheumatoid Arthritis

  1999cited by this paper
• Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

  1999cited by this paper
• The use of methotrexate in childhood rheumatic diseases.

  1998cited by this paper
• Preliminary definition of improvement in juvenile arthritis.

  1997cited by this paper
• Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.

  1997cited by this paper
• Patterns of expression of tumor necrosis factor alpha, tumor necrosis factor beta, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy.

  1996cited by this paper
• Patterns of expression of tumor necrosis factor α, tumor necrosis factor β, and their receptors in synovia of patients with juvenile rheumatoid arthritis and juvenile spondylarthropathy

  1996cited by this paper
• Juvenile rheumatoid arthritis in Rochester, Minnesota 1960-1993. Is the epidemiology changing?

  1996cited by this paper
• High dose methotrexate in the treatment of refractory juvenile rheumatoid arthritis.

  1995cited by this paper
• Serum cytokines in juvenile rheumatoid arthritis. Correlation with conventional inflammation parameters and clinical subtypes.

  1995cited by this paper
• Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing

  1994cited by this paper
• Treatment of lupus interstitial lung disease with intravenous cyclophosphamide.

  1994cited by this paper
• Local synthesis of both macrophage and T cell cytokines by synovial fluid cells from children with juvenile rheumatoid arthritis

  1994cited by this paper
• Measurement of health status in children with juvenile rheumatoid arthritis.

  1994cited by this paper
• First international conference on rheumatic diseases in pregnancy.

  1993cited by this paper
• Methotrexate in Juvenile Rheumatoid Arthritis

  1993cited by this paper
• Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.

  1993cited by this paper
• Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis.

  1992cited by this paper
• Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children's Study Group.

  1992cited by this paper
• Disease severity in rheumatoid arthritis: Relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures

  1992cited by this paper
• Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis.

  1992cited by this paper
• The health assessment questionnaire 1992: status and review.

  1992cited by this paper
• Comparison of Exact, Mid-p, and Mantel–Haenszel Confidence Intervals for the Common Odds Ratio Across Several 2 × 2 Contingency Tables

  1992cited by this paper
• Evaluation of methotrexate in the treatment of juvenile chronic arthritis according to the subtype.

  1991cited by this paper
• Induction of suppurative arthritis in rabbits by Haemophilus endotoxin, tumor necrosis factor-alpha, and interleukin-1 beta.

  1991cited by this paper
• Auranofin therapy for juvenile rheumatoid arthritis: results of the five-year open label extension trial.

  1991cited by this paper
• Involvement of the CD11b/CD18 integrin, but not of the endothelial cell adhesion molecules ELAM-1 and ICAM-1 in tumor necrosis factor-alpha-induced neutrophil toxicity.

  1991cited by this paper
• Induction of suppurative arthritis in rabbits by Haemophilus endotoxin, tumor necrosis factor-α, and interleukin-1β

  1991cited by this paper
• Identification of the major fibroblast growth factors released spontaneously in inflammatory arthritis as platelet derived growth factor and tumour necrosis factor‐alpha

  1991cited by this paper
• Auranofin in the treatment of juvenile rheumatoid arthritis.

  1990cited by this paper
• Auranofin in the treatment of juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The USA Pediatric Rheumatology Collaborative Study Group. The USSR Cooperative Children's Study Group.

  1990cited by this paper
• Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.

  1989cited by this paper
• Characteristics of responders and nonresponders to slow-acting antirheumatic drugs in juvenile rheumatoid arthritis.

  1988cited by this paper
• Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors

  1986cited by this paper
• Penicillamine and hydroxychloroquine in the treatment of severe juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind placebo-controlled trial.

  1986cited by this paper
• Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage

  1986cited by this paper
• Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts

  1985cited by this paper
• A TEST FOR HOMOGENEITY OF THE MARGINAL DISTRIBUTIONS IN A TWO-WAY CLASSIFICATION

  1955cited by this paper

• PAFLAR guidelines for oligoarticular juvenile idiopathic arthritis

  2026cites this paper
• Anti-Inflammatory and Synaptic Protective Effects of TNF-α Inactivation in the MDX Mouse Model

  2026cites this paper
• Outcomes of children with juvenile idiopathic arthritis receiving biological disease-modifying anti-rheumatic drugs: a retrospective single-centre experience from India

  2025cites this paper
• Examination of Behavioral and Neuropsychological Characteristics of Hungarian Patients with Juvenile Idiopathic Arthritis: A Cross-Sectional Analysis

  2025cites this paper
• Advances in pharmacotherapy of juvenile idiopathic arthritis

  2025cites this paper
• Effect of biologic treatments on growth in children with juvenile idiopathic arthritis: A systematic review

  2025cites this paper
• The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care

  2025cites this paper
• Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis.

  2025cites this paper
• Biosimilars in pediatric rheumatology: innovations, challenges, and opportunities

  2025cites this paper
• French protocol for the diagnosis and management of juvenile idiopathic arthritis including pediatric-onset Still's disease.

  2025cites this paper
• The impact of juvenile idiopathic arthritis on psychosocial outcomes: a systematic review and meta-analysis

  2025cites this paper
• Stochastic epigenetic mutation profiles as biomarkers of clinical activity in juvenile idiopathic arthritis: a multi-omic machine learning approach for gene prioritization

  2025cites this paper
• Update on Biologic Therapy in Juvenile Idiopathic Arthritis: A Five-year Narrative Review

  2025cites this paper
• Efficacy of biologic DMARDs in improving the clinical response of patients with polyarticular juvenile idiopathic arthritis: a meta-analysis of RCTs

  2025cites this paper
• Real life treatment in juvenile idiopathic arthritis: Is remission long lasting?

  2025cites this paper
• Literature analysis and implication of biologic therapy for children with non-systemic juvenile idiopathic arthritis in real-world settings.

  2025cites this paper
• Navigating the uncommon: challenges in applying evidence-based medicine to rare diseases and the prospects of artificial intelligence solutions

  2024cites this paper
• Drug therapy in juvenile spondyloarthritis

  2024cites this paper
• Vergleich der Therapie mit JAK-Inhibitoren bei der juvenilen idiopathischen Arthritis in der klinischen Praxis und in den Zulassungsstudien

  2024cites this paper
• Evaluation of etanercept (a tumor necrosis factor alpha inhibitor) as an effective treatment for joint disease in mucopolysaccharidosis type I. A case report with whole-body magnetic resonance imaging

  2024cites this paper
• Chronic TNF exposure induces glucocorticoid‐like immunosuppression in the alveolar macrophages of aged mice that enhances their susceptibility to pneumonia

  2024cites this paper
• Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence

  2024cites this paper
• Methotrexate for juvenile idiopathic arthritis.

  2024cites this paper
• Efficacy and safety of tumor necrosis factor inhibitors for systemic juvenile idiopathic arthritis: a systematic review.

  2024cites this paper
• 25 Years of Biologics for the Treatment of Pediatric Rheumatic Disease: Advances in Prognosis and Ongoing Challenges

  2024cites this paper
• Integrated analysis of multi-omics data for the discovery of biomarkers and therapeutic targets for juvenile idiopathic arthritis

  2024cites this paper
• Methotrexate injection: An old drug with a newly developing landscape

  2023cites this paper
• Individual and environmental determinants associated with longer times to access pediatric rheumatology centers for patients with juvenile idiopathic arthritis, a JIR cohort study

  2023cites this paper
• Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis.

  2023cites this paper
• Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis

  2023cites this paper
• How common is remission in rheumatoid factor-positive juvenile idiopathic arthritis patients? The multicenter Pediatric Rheumatology Academy (PeRA) research group experience

  2023cites this paper
• Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design

  2023cites this paper
• Etanercept for patients with juvenile idiopathic arthritis: drug levels and influence of concomitant methotrexate: observational study

  2023cites this paper
• What to Expect When Systemic Treatment in Juvenile Idiopathic Arthritis Is Withdrawn?

  2023cites this paper
• Abatacept as Monotherapy and in Combination With Methotrexate in Patients With Juvenile Idiopathic Arthritis: Analysis of 2 Phase III Trials

  2023cites this paper
• Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases

  2023cites this paper
• Efficacy and safety of TNF inhibitors in the treatment of juvenile idiopathic arthritis: a systematic literature review

  2023cites this paper
• Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.

  2023cites this paper
• Treatment of systemic juvenile idiopathic arthritis

  2023cites this paper
• Update on the systemic management of non-infectious uveitis in children and adolescents.

  2023cites this paper
• Biologic switching patterns among children with non-systemic juvenile idiopathic arthritis

  2023cites this paper
• JAK Inhibition in Juvenile Idiopathic Arthritis (JIA): Better Understanding of a Promising Therapy for Refractory Cases

  2023cites this paper
• Risk of tuberculosis in children with rheumatologic diseases treated with biological agents: A cross-sectional cohort study

  2023cites this paper
• Biological Agent Switching in Patients With Juvenile Idiopathic Arthritis

  2023cites this paper
• Latent classes of early response trajectories to biologics initiation in juvenile idiopathic arthritis: an analysis of four trials

  2022cites this paper
• Secukinumab in enthesitis-related arthritis and juvenile psoriatic arthritis: a randomised, double-blind, placebo-controlled, treatment withdrawal, phase 3 trial

  2022cites this paper
• A Comparison of International League of Associations for Rheumatology and Pediatric Rheumatology International Trials Organization Classification Systems for Juvenile Idiopathic Arthritis Among Children in a Canadian Arthritis Cohort

  2022cites this paper
• Probability of Response in the First Sixteen Weeks After Starting Biologics: An Analysis of Juvenile Idiopathic Arthritis Biologics Trials

  2022cites this paper
• B Cells on the Stage of Inflammation in Juvenile Idiopathic Arthritis: Leading or Supporting Actors in Disease Pathogenesis?

  2022cites this paper
• Dosing Variation at Initiation of Adalimumab and Etanercept and Clinical Outcomes in Juvenile Idiopathic Arthritis: A Childhood Arthritis and Rheumatology Research Alliance Registry Study

  2022cites this paper
• Biotherapy in juvenile idiopathic arthritis Moroccan patients: a single-center experience

  2022cites this paper
• 2021 American College of Rheumatology Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Oligoarthritis, Temporomandibular Joint Arthritis, and Systemic Juvenile Idiopathic Arthritis

  2022cites this paper
• Emerging therapies for juvenile arthritis: agents in early clinical trials

  2022cites this paper
• Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis-associated uveitis.

  2022cites this paper
• Juvenile idiopathic arthritis

  2022cites this paper
• Changing Patterns in Treatment, Remission Status, and Categories in a Long‐Term Nordic Cohort Study of Juvenile Idiopathic Arthritis

  2022cites this paper
• Innovationen in der Behandlung der juvenilen idiopathischen Arthritis

  2022cites this paper
• Relationship between juvenile idiopathic arthritis and periodontal diseases

  2022cites this paper
• Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): New perspectives on interdisciplinary care.

  2022cites this paper
• Towards molecular-pathology informed clinical trials in childhood arthritis to achieve precision medicine in juvenile idiopathic arthritis

  2022cites this paper
• Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches

  2021cites this paper
• Interfering with Interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA).

  2021cites this paper
• Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

  2021cites this paper
• Biosimilars in der pädiatrischen Rheumatologie

  2021cites this paper
• PRACTICAL MANAGEMENT of patients on anti-TNF therapy: Practical guidelines drawn up by the Club Rhumatismes et Inflammation (CRI).

  2021cites this paper
• 80 Meilensteine der Rheumatologie aus 80 Jahren – III: 1980–2000

  2021cites this paper
• Zytokin-Inhibitoren in der pädiatrischen Rheumatologie

  2021cites this paper
• "Extensive Proof-of-Concept Studies in TNF-Alpha Antagonists might be Responsible for A Delay of Patient Access in Pediatric Rheumatology"

  2021cites this paper
• A roadmap to using randomization in clinical trials

  2021cites this paper
• Low Etanercept Concentrations in Children With Obesity and Juvenile Idiopathic Arthritis.

  2021cites this paper
• Persistence and adherence to biologic therapies in juvenile idiopathic arthritis

  2021cites this paper
• Polyartikuläre Verlaufsformen der juvenilen idiopathischen Arthritis

  2021cites this paper
• Soluble CD127 potentiates IL‐7 activity in vivo in healthy mice

  2021cites this paper
• Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials

  2021cites this paper
• Re-treatment with etanercept is as effective as the initial firstline treatment in patients with juvenile idiopathic arthritis

  2021cites this paper
• Outcome Scores in Pediatric Rheumatology

  2021cites this paper
• Advancing the treatment of juvenile idiopathic arthritis.

  2021cites this paper
• Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registry

  2021cites this paper
• Therapeutic alliance is associated to treatment adherence in children with juvenile idiopathic arthritis.

  2021cites this paper
• Évènements indésirables infectieux chez des enfants atteints d’arthrite juvénile idiopathique et traités en vie réelle par biothérapies : données issues de la JIR cohorte

  2021cites this paper
• Pathogenesis and Treatment of Refractory Disease Courses in Systemic Juvenile Idiopathic Arthritis: Refractory Arthritis, Recurrent Macrophage Activation Syndrome and Chronic Lung Disease.

  2021cites this paper
• Juvenile Idiopathic Arthritis Treatment Updates.

  2021cites this paper
• Precision medicine in juvenile idiopathic arthritis-has the time arrived?

  2021cites this paper
• Pharmacosurveillance in Juvenile Idiopathic Arthritis.

  2021cites this paper
• Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis

  2021cites this paper
• Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans

  2021cites this paper
• Biomarkers of Response to Biologic Therapy in Juvenile Idiopathic Arthritis

  2021cites this paper
• Zytokine in der pädiatrischen Rheumatologie

  2021cites this paper
• Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial.

  2021cites this paper
• Manejo dos biológicos em crianças e adolescentes com doenças reumáticas autoimunes

  2021cites this paper
• Death Receptors and Their Ligands in Inflammatory Disease and Cancer.

  2020cites this paper
• Biological disease-modifying antirheumatic drugs in juvenile idiopathic arthritis of polyarticular course, enthesitis-related arthritis, and psoriatic arthritis: a consensus statement.

  2020cites this paper
• Long‐Term Outcomes in Juvenile Idiopathic Arthritis: Eighteen Years of Follow‐Up in the Population‐Based Nordic Juvenile Idiopathic Arthritis Cohort

  2020cites this paper
• Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial

  2020cites this paper
• Real‐World Effectiveness of Common Treatment Strategies for Juvenile Idiopathic Arthritis: Results From a Canadian Cohort

  2020cites this paper
• Rheumatologic Disorders

  2020cites this paper
• Approaches to Medical Therapy

  2020cites this paper
• TNF-alpha inhibitors for juvenile idiopathic arthritis

  2020cites this paper
• Early combination therapy with etanercept and methotrexate in JIA patients shortens the time to reach an inactive disease state and remission: results of a double-blind placebo-controlled trial

  2020cites this paper
• Overview of Juvenile Idiopathic Arthritis

  2020cites this paper